Subtotal $0.00
Feel Free To Contact Us at
- Phone:(888)-896-5577
- Email:dr.koffler@hmwcenter.com
Feel Free To Contact Us at
Dihexa has not entered established human clinical trials as of 2026. Current research is primarily limited to laboratory and animal studies examining memory, synaptic plasticity, cognition, and the HGF/c-Met signaling pathway. While some preclinical studies have reported promising findings, they do not establish that Dihexa is safe or effective in humans. The evidence also requires caution because a foundational 2013 paper carries an expression of concern, while a key 2014 mechanistic study was retracted in 2025 following concerns about data integrity.
A related HGF-pathway drug, fosgonimeton (ATH-1017), has been tested in human Alzheimer’s disease trials, including the Phase 2/3 LIFT-AD study. The trial did not meet its primary endpoint. However, fosgonimeton is a different compound and its results cannot be considered clinical evidence for or against Dihexa. For now, Dihexa remains an experimental research compound, with no established human dose, proven clinical benefit, or FDA-approved indication.
No established human clinical trial program for Dihexa itself has demonstrated safety or efficacy.
There are no established Phase 1, Phase 2, or Phase 3 clinical trials showing that Dihexa treats:
The FDA has also stated that it has not identified human exposure data for drug products containing dihexa acetate administered by any route. This means important questions about human safety, dosing, pharmacokinetics, and tolerability remain unanswered.
This distinction matters because online discussions can make Dihexa appear much further along in development than the evidence supports.
Dihexa is an experimental angiotensin IV-derived molecule that has been investigated for potential effects on neuronal signaling and synaptic plasticity.
Its chemical name is N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, and it has also been associated with the development code PNB-0408.
Researchers became interested in Dihexa partly because it was designed to be more resistant to enzymatic breakdown than some related compounds and showed brain exposure in experimental models.
However, brain penetration in animals does not establish human brain exposure. Human pharmacokinetic studies would be needed to determine how Dihexa behaves in people.
The central scientific interest has been neuroplasticity.
Neuroplasticity describes the nervous system’s ability to modify connections between neurons. These changes are fundamental to learning, memory, adaptation, and recovery from certain forms of neurological injury.
Researchers have therefore investigated whether manipulating growth-factor signaling could influence synaptic development and neuronal function.
This led to interest in the hepatocyte growth factor (HGF)/c-Met pathway.
Hepatocyte growth factor (HGF) is a signaling protein involved in processes such as cell survival, growth, movement, development, and tissue repair.
Despite its name, HGF is not limited to the liver. Researchers have also studied its role in the nervous system, including potential effects on neuronal survival and synaptic development.
c-Met is a receptor tyrosine kinase that responds to HGF. Once activated, it can influence several cellular processes.
In neurological research, HGF/c-Met signaling has been investigated in relation to:
However, HGF/c-Met signaling has broad biological functions beyond the brain, including roles in cell growth and movement. That makes the pathway scientifically interesting—but also highlights why safety evaluation is essential before attempting long-term therapeutic use.
Early research involving Dihexa and related angiotensin IV analogues produced encouraging findings in animal models.
A 2013 study investigated metabolically stabilized angiotensin IV analogues as potential cognitive-enhancing or antidementia compounds. Some experiments reported behavioral effects in rodents.
Later research also investigated Dihexa in experimental Alzheimer’s disease models.
For example, a 2021 study using an APP/PS1 mouse model reported improvements in measures of spatial learning and cognitive function. Researchers also observed changes involving neuronal, inflammatory, and signaling markers.
These findings are scientifically relevant because they provide hypotheses for further research.
But they remain preclinical findings.
A mouse performing better on a memory task does not establish that the same compound will slow Alzheimer’s disease, improve human memory, or increase quality of life in patients.
One of the most widely repeated claims about Dihexa is that it may be dramatically more potent than brain-derived neurotrophic factor (BDNF) at promoting synaptic growth.
This claim requires significant qualification.
A key 2014 paper investigating the HGF/c-Met mechanism and synaptogenic effects associated with Dihexa was retracted in 2025. According to the retraction notice, a Washington State University investigation identified falsified and/or fabricated data in specified figures and related data.
The original 2013 paper concerning metabolically stabilized angiotensin IV analogues also carries an expression of concern.
This does not mean that every Dihexa study is invalid. It does mean that findings from the affected research cannot be treated as established evidence, and claims based heavily on those papers should be presented cautiously.
Independent replication is particularly important when evaluating experimental compounds.
There is currently no human clinical evidence establishing Dihexa as an effective Alzheimer’s treatment.
Some animal studies have reported improvements in cognitive measures and changes in neuronal or inflammatory markers. These findings may justify further scientific investigation, but they do not demonstrate clinical efficacy.
Alzheimer’s disease is also considerably more complex than any single animal model. Human disease involves interacting processes including amyloid and tau pathology, neuroinflammation, vascular factors, aging, genetics, and neuronal dysfunction.
Fosgonimeton is important because it provides a human clinical data point involving the broader HGF pathway.
However, it is essential to understand that fosgonimeton is a different compound from Dihexa.
Fosgonimeton progressed into human clinical development, including the LIFT-AD Phase 2/3 trial in people with mild-to-moderate Alzheimer’s disease.
The 26-week randomized, double-blind, placebo-controlled study enrolled 312 participants. Its primary endpoint was a Global Statistical Test incorporating cognitive and functional measures.
The trial did not meet its primary endpoint, and key secondary cognitive and functional measures also did not achieve statistical significance.
The result does not prove that Dihexa works or fails. Different molecules can have very different pharmacology, safety profiles, and clinical effects.
However, the result is a useful reminder that a compelling biological mechanism does not automatically translate into meaningful clinical benefit.
The most accurate answer is:
Dihexa’s human safety profile is unknown.
There is not enough human clinical evidence to establish a reliable therapeutic dose or adequately characterize:
The HGF/c-Met pathway is involved in cellular growth and survival and is also relevant to cancer biology. This does not establish that Dihexa causes cancer, but it reinforces why long-term safety studies would be necessary before widespread therapeutic use.
No.
Dihexa is not an FDA-approved treatment for Alzheimer’s disease, dementia, memory loss, brain fog, stroke, traumatic brain injury, Parkinson’s disease, or cognitive enhancement.
There is also no validated human dosing regimen established through adequate clinical trials.
This is an important distinction for anyone researching Dihexa online: experimental availability or discussion by practitioners is not the same as regulatory approval or clinical validation.
There is currently insufficient human clinical evidence to establish Dihexa as a treatment for brain fog, Long COVID, stroke recovery, concussion, or traumatic brain injury.
Preclinical research into neuroplasticity may provide theoretical reasons for studying these possibilities. But a biological hypothesis is not the same as a demonstrated treatment.
For symptoms such as brain fog or cognitive decline, identifying the underlying cause is important because symptoms can have many potential explanations.
| Evidence | Current status |
|---|---|
| Laboratory research | Some evidence |
| Animal studies | Some evidence |
| Alzheimer’s animal models | Some evidence |
| Human pharmacokinetic studies | Not established |
| Phase 1 human trial | None established |
| Phase 2 human trial | None established |
| Phase 3 human trial | None established |
| FDA-approved indication | No |
| Validated human dose | No |
| Established long-term human safety | No |
| Proven Alzheimer’s treatment | No |
If Dihexa were to progress toward legitimate clinical development, researchers would first need robust evidence addressing several fundamental questions.
Human pharmacokinetics: How is Dihexa absorbed, metabolized, distributed, and eliminated in humans?
Phase 1 safety: What doses are tolerated, and what adverse effects occur?
Phase 2 efficacy: Does Dihexa produce measurable improvements in validated clinical outcomes?
Long-term safety: What happens with repeated exposure over months or years?
Independent replication: Can important preclinical findings be reproduced by independent laboratories, particularly given concerns surrounding some foundational research?
Only after convincing evidence from these stages could researchers meaningfully assess whether Dihexa has therapeutic potential.
Dihexa remains an experimental compound with limited clinical evidence. While animal studies have explored its potential effects on cognition, synaptic plasticity, and HGF/c-Met signaling, there are no established human trials confirming its safety or effectiveness. Concerns surrounding foundational research further reinforce the need for caution.
Dihexa is not an FDA-approved treatment for Alzheimer’s disease, dementia, brain fog, or cognitive enhancement. Until well-designed human trials establish its safety, appropriate dosing, and clinical benefits, it should be considered a research compound rather than a proven medical therapy.
No. There is no established human clinical trial program for Dihexa itself. FDA also reports that it has not identified human exposure data for drug products containing dihexa acetate administered by any route.
Preclinical research has investigated potential effects involving memory, synaptic plasticity, neuronal signaling, and neurodegenerative disease models.
There is no established human evidence demonstrating that Dihexa treats Alzheimer's disease.
Some animal studies have reported improvements in cognitive measures and changes in neuronal and inflammatory markers. (PubMed)
Preclinical research has investigated effects on synaptic and neuronal growth pathways. However, claims about clinically meaningful neurogenesis in humans are not established.
This claim comes from early laboratory research, but the key 2014 paper supporting the HGF/c-Met mechanism was retracted in 2025 after a research-integrity investigation. The claim should therefore not be presented as an established fact.
Yes. The 2013 paper evaluating metabolically stabilized angiotensin IV analogues has an expression of concern recorded in PubMed.
No. It means specific published findings can no longer be treated as reliable evidence from that paper. Other independent or separate studies must be evaluated individually.
Fosgonimeton, also known as ATH-1017, was a separate drug candidate designed to positively modulate the HGF pathway. It is not the same compound as Dihexa.
Its Phase 2/3 LIFT-AD trial did not meet its primary endpoint or key secondary cognitive and functional endpoints with statistical significance. Development was subsequently paused.
No. They are different compounds. Fosgonimeton's results are relevant to the broader HGF-pathway hypothesis but cannot directly prove or disprove Dihexa's effects.
Earn how Dihexa may support your goals—safely, responsibly, and backed by functional expertise
